Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 1 pseudogene 9 (HMGB1P9) is classified as a pseudogene in humans. Pseudogenes are genomic DNA sequences similar to normal genes but typically non-functional; they are generally not transcribed into functional proteins and do not play direct biological or pathological roles. While the parental gene, HMGB1, is a well-studied DNA-binding protein involved in inflammation, immunity, and disease pathways, HMGB1P9 lacks evidence of protein-coding function, therapeutic targeting, or disease association, and is not considered a drug target. HMGB1P9 is a pseudogene and not a protein-coding gene, enzyme, receptor, or other therapeutic target. No role in disease, mechanism of action, or drug interaction is attributed to HMGB1P9 in the current literature or authoritative databases. If you are interested in HMGB1 (not HMGB1P9), that is an active protein involved in many physiological and pathological processes, but HMGB1P9 itself is not a functional target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 1 pseudogene 9 (HMGB1P9).